What is the current stock price of Cerus Corporation (CERS)?

As of the latest market data, Cerus Corporation (CERS) is trading at $1.89. The stock has seen a loss of -1.05% today.

Does Cerus Corporation (CERS) pay a dividend?

Based on current data, Cerus Corporation does not have a confirmed active dividend policy.

What is the market cap of Cerus Corporation?

The current market capitalization of Cerus Corporation (CERS) is approximately unavailable.

CERS

Cerus Corporation·Healthcare

1.89

1.047%(−0.02)

Market Closed

2.06

8.995%(+0.17)

After Hours

Last Updated: — ET

52W L: $1.1552W H: $2.96

CERS NEWS

defenseworld.net

Mar 18

Kevin Dennis Green Sells 127,544 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ: CERS - Get Free Report) CFO Kevin Dennis Green sold 127,544 shares of the company's stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $1.66, for a total value of $211,723.04. Following the sale, the chief financial officer owned 1,040,551 shares in the company, valued

defenseworld.net

Mar 18

Vivek Jayaraman Sells 165,200 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ: CERS - Get Free Report) COO Vivek Jayaraman sold 165,200 shares of the stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $1.66, for a total value of $274,232.00. Following the sale, the chief operating officer owned 1,747,674 shares of the company's stock, valued at

defenseworld.net

Mar 18

Chrystal Jensen Sells 113,008 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ: CERS - Get Free Report) insider Chrystal Jensen sold 113,008 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $1.66, for a total value of $187,593.28. Following the transaction, the insider owned 946,131 shares of the company's stock, valued at

businesswire.com

Mar 16

Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William “Obi” Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. “Following a thorough succession planning process, this transition represents a natural step as we prepare for the nex.

defenseworld.net

Mar 9

Cerus Details INTERCEPT Growth Plan, BCA Deal Upside and 2026 RBC Milestones at TD Cowen Conference

Cerus (NASDAQ: CERS) executives used a presentation and fireside chat at the TD Cowen Healthcare Conference to reiterate the company's focus on making its INTERCEPT Blood System a global standard of care for transfusion medicine, while outlining commercial priorities across U.S. platelets, international expansion, and the company's INTERCEPT Fibrinogen Complex (IFC) franchise. Chairman, President and CEO

seekingalpha.com

Mar 5

Cerus's Record 2025 Sets It Up For Another Leg Higher

CERS' INTERCEPT platform (kits + illuminators) is scaling globally, with record 2025 results. They've also grown their adoption across ~40 countries. INT200 received European approval and launched. They also have a US PMA filing targeted for 2026. This means CERS may soon have another hardware refresh cycle, with future kit pull-through.

Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Sector

Healthcare

Industry

Medical - Devices

Employees

614

IPO Date

1997-01-31

Beta

1.63

Websitewww.cerus.com↗